Finasteride for Hair Loss: Does It Work? Evidence and Results
Medically reviewed by [Reviewer Name, MD, Dermatology] | Last reviewed: August 2026 | Editorial policy | Sources
Finasteride 1 mg (brand name Propecia; widely available as generic) is the only FDA-approved oral medication for male androgenetic alopecia (AGA, male pattern hair loss). It works by blocking the enzyme that produces DHT, the androgen that causes hair follicle miniaturization in men genetically susceptible to AGA. In clinical trials, finasteride halted or improved hair loss in approximately 83% of treated men at 12 months and produced visible regrowth in about 48% — compared to 7% on placebo.
What Is Male Pattern Hair Loss (AGA)?
Androgenetic alopecia is the most common form of hair loss in men, affecting approximately 50% of men by age 50 and up to 70% by age 70 (Hamilton, 1951; Norwood, 1975). It is caused by the interaction of genetic predisposition and androgens — specifically, dihydrotestosterone (DHT).
In men with AGA, scalp follicles in susceptible regions (primarily the vertex/crown and frontal scalp) express an increased density of androgen receptors and are hypersensitive to DHT. When DHT binds to these receptors, it progressively shortens the anagen (growth) phase of the hair cycle and miniaturizes the follicle, producing progressively finer, shorter, and eventually near-invisible vellus hairs. This miniaturization follows predictable patterns, classified by the Norwood–Hamilton scale (Types I–VII).
The key insight that led to finasteride’s development: men with a congenital deficiency of 5-alpha-reductase Type II (the enzyme that makes DHT) do not develop AGA, regardless of testosterone levels (Imperato-McGinley et al., 1974). Finasteride recreates this DHT-deficient state pharmacologically.
How Finasteride Treats Hair Loss
Finasteride 1 mg taken daily inhibits Type II 5-alpha-reductase in the scalp and other tissues, reducing:
- Scalp DHT by approximately 64% (Dallob et al., 1994)
- Serum DHT by approximately 70%
This reduction interrupts the DHT-driven miniaturization cycle. Existing miniaturized follicles can partially recover — producing thicker, longer terminal hairs — and the ongoing progression of AGA is significantly slowed or halted. The drug does not grow new follicles where follicular units have been permanently lost.
Clinical Evidence: What the Trials Show
Pivotal 1-Year RCTs (Kaufman et al., 1998)
The FDA approval for finasteride 1 mg for AGA was based on two Phase III double-blind, randomized, placebo-controlled trials (Study 1: n=1,553; Study 2: n=1,215) conducted across multiple centers. Men aged 18–41 with mild to moderate vertex AGA (Norwood–Hamilton Type II–IV) were enrolled.
| Efficacy Endpoint | Finasteride 1 mg (n=945) | Placebo (n=606) |
|---|---|---|
| Hair count change at vertex (hairs/cm²) | +7.1 | −10.6 |
| Hair growth improved (investigator global assessment) | 48% | 7% |
| Hair growth maintained or improved | 83% | 28% |
| Hair loss continued (worsened) | 17% | 72% |
| Improvement in hair growth (patient self-assessment) | 42% | 10% |
5-Year Extension Study
In the 5-year open-label extension study (Kaufman et al., 1999; Whiting et al., 2003):
- Mean hair count in the finasteride group remained above baseline throughout 5 years
- Men who had been on placebo for 1 year and then switched to finasteride caught up partially but never reached the hair count of men who had started finasteride at year 1 — underscoring the importance of early treatment
- 65% of finasteride-treated men showed scalp hair growth above baseline at 5 years vs. 7% on continuous placebo
- The difference in mean hair count between finasteride and placebo groups reached 277 hairs in a 1-inch diameter disk by year 5 — a highly visible clinical difference
10-Year Long-Term Data
An open-label 10-year prospective study (Rossi et al., 2011; n=118 men) found that 99.1% of patients maintained or increased their hair count over 10 years of continuous finasteride 1 mg therapy. A 10-year Japanese study (Yanagisawa et al., 2012; n=801) reported that 91.5% of patients showed measurable hair growth improvement with continuous use. These data indicate that clinical benefit is maintained with long-term uninterrupted treatment.
Who Finasteride Is (and Is Not) For
| Group | Finasteride for AGA? | Notes |
|---|---|---|
| Adult men with vertex or mid-scalp AGA | Yes — FDA-approved first-line | Norwood–Hamilton Types II–V; most evidence at vertex |
| Men with frontal hairline recession only | Possibly — discuss with physician | Less robust evidence at hairline vs. vertex; may slow progression |
| Men with very advanced AGA (Norwood VI–VII) | Limited benefit expected | Most follicles irreversibly lost; can prevent further loss but not rebuild |
| Men under 18 | No — not studied; not indicated | AGA rarely presents before adulthood |
| Women (premenopausal) | No — contraindicated in potential pregnancy | Pregnancy Category X; teratogenic in male fetuses |
| Women (postmenopausal, off-label) | Off-label only; physician judgment | Not FDA-approved for women; limited evidence; see women’s guide |
How Long Until You See Results?
Finasteride acts within hours of the first dose to suppress DHT — but visible hair results take months because of the biology of the hair cycle. A typical timeline:
- Weeks 1–8: No visible change; some men experience a temporary “finasteride shed” — an increase in shedding as follicles synchronize into the growth phase. This is expected and not a sign of failure.
- Months 3–6: Hair loss typically stabilizes. The rate of loss slows or halts in the majority of responders. This is usually the first clinical sign that the drug is working.
- Months 6–12: The window of most noticeable visible improvement for most responders. Hair density and caliber increase as miniaturized follicles recover.
- 12–24 months: Peak response for most men. Continued daily use maintains benefit.
Finasteride must be taken continuously to maintain its effects. Stopping treatment typically results in reversal of benefit within 6–12 months as DHT levels return to baseline.
Detailed timeline: What to expect at 3, 6, 12, and 24 months
Side Effects Relevant to Hair Loss Use
At the 1 mg/day dose, sexual side effects occur in a small minority above placebo rates:
| Side Effect | Finasteride 1 mg | Placebo |
|---|---|---|
| Decreased libido | 1.8% | 1.3% |
| Erectile dysfunction | 1.3% | 0.7% |
| Ejaculation disorder | 0.8% | 0.4% |
| Gynecomastia | 0.4% | 0.2% |
In most men who experienced sexual side effects in trials, they resolved after stopping finasteride. The 2012 FDA label update acknowledged reports of persistent sexual side effects after discontinuation (Post-Finasteride Syndrome). Men with personal or family history of depression should discuss this with their physician; the EMA (2019) added depression and suicidal ideation to the European label.
Complete finasteride side effects guide | Post-Finasteride Syndrome
Dosage and Getting a Prescription
The approved dose for male AGA is finasteride 1 mg once daily, taken orally with or without food. Generic finasteride 1 mg is therapeutically identical to Propecia and substantially cheaper ($15–$35/month vs. $70–$100+ for brand).
Finasteride requires a prescription in the US. Options include a primary care physician, dermatologist, or telehealth platform. Several telehealth services (Hims, Keeps, Roman) offer online consultation and finasteride prescription with same-day dispensing.
Finasteride cost comparison: generics, GoodRx, and telehealth
Frequently Asked Questions
Does finasteride work for a receding hairline?
Finasteride’s strongest evidence is at the vertex and mid-scalp. Evidence for frontal hairline restoration is more limited. However, finasteride can slow or halt frontal recession and may produce some improvement, particularly when started early. Men hoping to restore a significantly receded hairline should discuss realistic expectations with a dermatologist; hair transplant surgery may be appropriate in conjunction with medical therapy.
Will finasteride work if I have already lost a lot of hair?
Finasteride is most effective at preventing further loss and recovering partially miniaturized follicles. In areas where follicular units have been completely and permanently lost (smooth bald scalp with no follicles), regrowth is not expected. Starting earlier in the course of hair loss yields better results than starting after extensive loss. A dermatologist can assess whether your hair loss pattern and stage makes you likely to respond.
Can I take finasteride every other day?
The FDA-approved dosing is 1 mg every day. Some men explore every-other-day dosing to reduce side effect exposure, and given finasteride’s 6–8 hour half-life and the slow dissociation of its enzyme inhibition complex, there is pharmacological rationale for partial efficacy. However, this is off-label and no large RCT has confirmed equivalent efficacy at alternate-day dosing. Discuss any dosing modifications with your prescribing physician.
About this page: Reviewed by [Reviewer Name, MD, Dermatology]. Data sourced from FDA prescribing information, pivotal RCTs, and peer-reviewed long-term studies. Last reviewed August 2026. Editorial policy.
Sources
- Kaufman KD, et al. “Finasteride in the treatment of men with androgenetic alopecia.” J Am Acad Dermatol. 1998;39(4):578–589.
- Dallob AL, et al. “The effect of finasteride on scalp skin testosterone and dihydrotestosterone concentrations.” J Clin Endocrinol Metab. 1994;79(3):703–706.
- Rossi A, et al. “Finasteride, 1 mg daily administration on male androgenetic alopecia: 10-year follow-up.” Dermatol Ther. 2011;24(4):455–461.
- Merck & Co. Propecia (finasteride 1 mg) US Prescribing Information. Revised 2022.